astrazeneca: fusion acquisition will be a cost effective-investment that can improve cancer outcomes
Published 4 months ago • 268 plays • Length 3:22Download video MP4
Download video MP3
Similar videos
-
5:34
astrazeneca lifts guidance as demand for cancer drugs grows
-
5:03
astrazeneca ceo: objective is to replace chemotherapy
-
8:42
astrazeneca ceo pascal soriot goes one-on-one with jim cramer
-
2:42
astrazeneca 'within striking distance' of curing some cancers, ceo says | cnbc conversation
-
2:00
astrazeneca chair: health care systems around the world can benefit from investment in technology
-
3:44
astrazeneca to buy alexion pharmaceuticals in $39 billion deal
-
1:19
astrazeneca's antibody cocktail helps prevent covid for at least 6 months
-
5:29
revolutionary new cancer treatment at nyu
-
5:33
sudden cardiac death affecting 12 young people every week - what is this ‘silent killer’?
-
6:35
could covid vaccine technology cure cancer? | dw news
-
0:36
astrazeneca's billion-dollar bet: revolutionizing cancer treatment? | tomorrow world
-
7:27
astrazeneca ceo soriot on pharmaceuticals in china
-
3:48
new cancer drug data announced: here's what to know
-
4:51
ai's greatest impact will be on medical research, says author ron razmi
-
3:44
not clear yet if we need a third booster for the vaccine: astrazeneca ceo
-
0:54
pfizer ceo: cancer drugs will be our next big contribution to the world
-
0:33
astrazeneca surges after hhs provides $500 million for covid-19 antibody treatment development
-
0:30
sa first to receive the astrazeneca vaccine
-
2:38
leading by disruption in cancer care
-
1:00
astrazeneca's strategic acquisition in oncology
-
6:11
astrazeneca ceo talks blowout earnings, global growth, new drugs, and pricing